Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T2C001-AMI
- Development stage
- Unknown
- Lead developer
- T2Cure
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary, Intra-arterial
01
Overview
T2C001-AMI is an autologous cellular therapeutic developed by the German biopharmaceutical company t2cure GmbH. The therapy consists of mononuclear stem cells harvested from the patient's own bone marrow, which are then processed and re-administered to promote tissue repair and vascular growth. T2C001-AMI has primarily been developed for cardiovascular and peripheral vascular indications, specifically Buerger's Disease (thromboangiitis obliterans) and acute myocardial infarction (AMI). The therapy works by inducing neovascularization (angiogenesis) in ischemic tissues through the release of paracrine factors and direct cellular contribution to vessel formation. It received orphan drug designation from the FDA and EMA for Buerger's Disease and was commercially available in Germany as of 2010 following the completion of Phase II clinical trials.
- Other names
- t2c001t-2c001t 2c001autologous bone marrow-derived mononuclear cells
Beyond the preview
Go deeper on T2C001-AMI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T2C001-AMI.